Patent expiry arbitrage is a market entry strategy that exploits the moment legal protection on a proven product lapses, allowing new entrants to manufacture, improve, or rebrand the same underlying technology — typically at lower cost or with superior distribution.
Section 1
How It Works
Every patent is a ticking clock. For up to 20 years, a patent grants its holder a legal monopoly — the right to exclude competitors from making, using, or selling a specific invention. During that window, the patent holder captures monopoly rents: pricing power unchecked by competition, margins that reflect exclusivity rather than cost of production. When the clock runs out, that monopoly evaporates overnight. The underlying technology enters the public domain, and anyone can manufacture it.
The cognitive shift this framework demands is simple: stop looking for things to invent and start looking for things that are about to become unprotected. The patent system itself is your deal flow engine. Every granted patent has a public expiration date. The FDA publishes lists of drug patents approaching expiry through its Orange Book. The USPTO maintains searchable databases. The information is free, the timing is predictable, and the demand has already been validated — often by billions of dollars in annual sales.
The underlying principle is that patent-protected products create artificially suppressed supply. Consumers who want the product but can't afford the monopoly price represent latent demand. When the patent expires, that demand doesn't need to be created — it needs to be served. The first movers who are ready with manufacturing capacity, regulatory approvals, and distribution on the day the patent lapses capture a disproportionate share of that demand release.
This is most visible in pharmaceuticals, where generic drugs routinely capture 80–90% of a branded drug's volume within a year of patent expiry. But the principle applies anywhere patents create pricing power: semiconductors, industrial chemicals, medical devices, consumer electronics components, agricultural biotechnology, and increasingly, software-adjacent hardware. The Hatch-Waxman Act of 1984 codified this dynamic in pharma by creating an abbreviated pathway for generic drug approval, but the strategic logic predates the legislation. Wherever a patent expires on a product with proven demand, the opportunity exists.
"The best businesses are the ones where you already know there's demand. You're not guessing — you're executing."
The mechanics vary by industry, but the playbook has three constants: identify the expiring protection, prepare your supply chain and regulatory approvals in advance, and launch the moment the window opens. The companies that win are not the ones who notice the expiry — that information is public. They're the ones who spent 18–36 months preparing so they could ship on Day One.
Section 2
When to Use This Framework
✓
Best Conditions for Patent Expiry Arbitrage
| Dimension | Ideal conditions |
|---|
| Founder profile | Operators with regulatory expertise and supply chain access. You need someone who understands FDA filings, manufacturing partnerships, or patent law — not a visionary product designer. Domain specialists in pharma, chemicals, medical devices, or hardware manufacturing are the ideal fit. |
| Stage | Pre-launch planning, 18–36 months before the target patent expires. The framework rewards preparation over speed. By the time the patent lapses, your product should be manufactured, approved (if applicable), and ready for distribution. Starting after expiry means you've already lost the first-mover window. |
| Market conditions | Best when the patent-protected product has high consumer awareness, significant annual revenue ($100M+), and pricing that is widely perceived as excessive. The larger the gap between production cost and retail price, the more margin available for new entrants. |
| Competitive environment | Ideal when few competitors are preparing for the same expiry window, or when the incumbent has signaled it will not aggressively defend through authorized generics, patent evergreening, or litigation. Markets where the incumbent is distracted — facing other patent cliffs, M&A activity, or pipeline problems — are especially attractive. |
| Regulatory landscape | Strongest in jurisdictions with clear abbreviated approval pathways — ANDA filings in the U.S., ABPI processes in the EU, or equivalent frameworks. Markets without streamlined generic/biosimilar approval processes dramatically increase time-to-market and reduce the advantage of early preparation. |
| Capital requirements | Moderate to high. Generic pharma requires manufacturing facilities and regulatory filings that can cost $1–5M per product. Consumer product rebrands (like Hims) require less manufacturing capital but significant marketing spend. Hardware and industrial applications vary widely. |
The framework is particularly fertile right now. Between 2024 and 2030, an estimated $250 billion in branded pharmaceutical revenue faces patent expiry, including blockbusters like Humira (adalimumab, already off-patent with biosimilars launching), Keytruda (pembrolizumab, patent expiry expected around 2028), and Eliquis (apixaban, facing patent challenges). Beyond pharma, key patents in CRISPR gene-editing technology, certain 5G communication protocols, and advanced battery chemistries are approaching expiry or facing challenges — each representing a distinct entry window for prepared operators.
Section 3
When It Misleads
⚠
Failure Modes & Blind Spots
| Blind spot | What goes wrong |
|---|
| Patent evergreening | The incumbent files secondary patents on formulations, delivery mechanisms, or manufacturing processes that extend effective exclusivity well beyond the original patent's expiry. AbbVie built a "patent thicket" of over 100 patents around Humira, delaying biosimilar competition in the U.S. until 2023 — nearly a decade after the core compound patent expired in Europe. |
| Authorized generics | The incumbent launches its own generic version, often through a subsidiary, cannibalizing the market before independent generics can gain traction. This is a deliberate defensive strategy — the incumbent accepts lower margins to deny volume to competitors. Pfizer did this with Lipitor through its own authorized generic. |
| Brand loyalty moats | In some categories, consumers have such strong brand attachment that generic alternatives struggle despite identical formulations. This is less common in pharma (where pharmacists and insurers drive substitution) but significant in consumer products, where the original brand's marketing spend creates switching costs that price alone can't overcome. |
| Race-to-the-bottom pricing | When dozens of generic manufacturers target the same patent expiry simultaneously, margins collapse rapidly. In commodity generics, prices can fall 90%+ within two years of expiry. If you're the fifteenth entrant with no differentiation, you're competing on manufacturing cost alone — a game won by the largest-scale producers in India and China. |
The single most common mistake is treating patent expiry as the only barrier to entry. The patent is the legal barrier, but the real barriers are often manufacturing capability, regulatory approval timelines, distribution relationships, and brand trust. A patent expiring doesn't mean you can ship tomorrow — it means you can start the process of competing. The winners are the ones who started that process years before expiry day.
Section 4
Step-by-Step Process
Step 1 — ScoutBuild a patent expiry pipeline
Systematically identify high-value patents expiring in the next 3–7 years. In pharma, the FDA's Orange Book lists every approved drug and its associated patents with expiry dates. For non-pharma industries, use USPTO and Google Patents to search by technology category and filing date (add 20 years for expiry). Prioritize products with annual revenue exceeding $500M, high consumer awareness, and significant price premiums over production cost. Build a ranked pipeline of 10–20 targets.
Step 2 — AnalyzeMap the competitive and regulatory landscape
For each target, answer three questions: How many competitors are already preparing to enter? What is the incumbent's likely defensive strategy (evergreening, authorized generics, litigation)? What is the realistic regulatory timeline in your target jurisdiction? In pharma, check Paragraph IV certification filings to see who else has filed ANDAs. In other industries, monitor patent challenge proceedings and competitor patent filings. Eliminate targets where the competitive field is already crowded or the incumbent's patent thicket is impenetrable.
Step 3 — DifferentiateDefine your value-add beyond price
Pure generic competition is a commodity game. The highest-value plays add something the original never offered: a better delivery mechanism (Hims turned generic sildenafil into a telehealth-first subscription), a new formulation (extended-release versions, combination products), superior branding and distribution (DTC channels the incumbent ignores), or a different customer segment entirely. Document your differentiation thesis — this is what separates a $10M generic manufacturer from a $1B brand.
Step 4 — PrepareSecure manufacturing, regulatory filings, and distribution 18–36 months before expiry
Begin regulatory filings as early as legally permitted. In the U.S., Paragraph IV ANDA filings can be submitted up to four years before patent expiry, and the first filer receives 180 days of generic exclusivity — an enormously valuable window. Secure manufacturing partnerships or build capacity. Lock in distribution agreements with pharmacies, retailers, or DTC platforms. The goal is to be ready to ship within days of the patent lapsing, not months.
Step 5 — LaunchExecute a coordinated market entry on Day One
Launch with aggressive pricing (typically 20–80% below the branded product), coordinated marketing that emphasizes equivalence and value, and distribution that reaches the incumbent's existing customer base. In pharma, work with pharmacy benefit managers and insurers to secure formulary placement. In consumer products, use DTC channels and social media to reach price-sensitive customers directly. The first 90 days after patent expiry determine market share for years to come.
Section 5
Questions to Ask Yourself
DiscoveryWhat patents expiring in the next 3–7 years protect products with $500M+ in annual revenue?
Is the demand for this product growing, stable, or declining — and will it still be relevant when the patent lapses?
What is the gap between the incumbent's retail price and the estimated production cost of a generic or unbranded version?
Are there adjacent patents (formulation, delivery, manufacturing process) that could block entry even after the core patent expires?
Competitive AssessmentHow many competitors have already filed ANDAs, biosimilar applications, or equivalent regulatory submissions for this product?
Has the incumbent signaled a defensive strategy — authorized generics, patent thickets, pay-for-delay settlements?
Can I realistically be among the first 3 entrants, or will I be the fifteenth generic in a commoditized market?
Is there a Paragraph IV first-filer opportunity that would grant me 180 days of generic exclusivity?
DifferentiationHow can I improve upon the original — better formulation, superior delivery, modern branding, DTC distribution, or a new customer segment?
Is there a way to repackage this off-patent technology for a market the incumbent never served?
Can I build a brand around this product that transcends generic commodity status?
Execution RiskWhat is the realistic regulatory approval timeline, and can I absorb a 12–24 month delay without running out of capital?
Do I have access to manufacturing capacity that meets regulatory standards (cGMP for pharma, relevant certifications for other industries)?
What happens to my unit economics if the incumbent launches an authorized generic at a lower price than I can match?
Am I prepared for patent infringement litigation, even if I believe my position is legally sound?
Section 6
Company Examples
Section 7
Adjacent Frameworks
Patent expiry arbitrage doesn't operate in isolation. Here's how it connects to the broader strategic toolkit:
Pairs well withRecreate boring but high value consumer products with hot rebrands
Patent expiry gives you the legal right to manufacture. This framework gives you the brand strategy. Hims is the canonical example: generic sildenafil plus modern DTC branding equals a billion-dollar company. The combination is more powerful than either alone.
Pairs well withTake something expensive and only accessible to rich people and make it accessible to everyone else
Patent-protected products are often priced for affluent consumers or well-insured patients. When the patent expires, the democratization opportunity is immediate — same product, fraction of the price, broader distribution. This pairing is the core logic of the entire generic pharmaceutical industry.
In tension withCategory creation
Patent expiry arbitrage is fundamentally about entering an existing category with a known product. Category creation asks you to build something that doesn't exist yet. They're opposing strategies — one minimizes demand risk, the other maximizes it. Use patent expiry when you want certainty; use category creation when you want ceiling.
In tension withInvent a new sport
Inventing a new sport means creating entirely new competitive dynamics. Patent expiry arbitrage means entering a game with well-established rules. The tension is between originality and replication — both valid, but they demand different founder temperaments and risk tolerances.
Section 8
Analyst's Take
Faster Than Normal — Editorial ViewMy honest read: patent expiry arbitrage is one of the most predictable opportunity-generation frameworks in business — and precisely because of that predictability, it's both more accessible and more dangerous than most founders realize.
The accessibility is obvious. Unlike most startup frameworks that require you to identify hidden demand or predict behavioral shifts, patent expiry gives you a public calendar of when monopolies end and a public record of how much revenue those monopolies generate. You can literally build a spreadsheet of opportunities ranked by revenue at risk, competitive density, and regulatory complexity. No other framework offers this level of informational clarity at the ideation stage.
The danger is equally clear: everyone else has the same spreadsheet. The FDA Orange Book is not a secret. Every generic pharmaceutical company in the world employs teams whose sole job is to monitor patent expiries and file ANDAs. The question is never "is this an opportunity?" — it's "can I capture enough of this opportunity to build a durable business before margins compress to zero?"
The founders who win here fall into two categories. The first are scale operators — companies like Teva and Mylan that industrialize the process, filing hundreds of ANDAs and winning through manufacturing efficiency and regulatory speed. This is a capital-intensive, operationally complex game that rewards experience and infrastructure. It's not a first-time founder's play.
The second — and far more interesting for the readers of this publication — are reframers. These are founders who look at an off-patent product and ask not "how do I make this cheaper?" but "how do I make this better in a way the incumbent never bothered to?" Hims didn't compete on price alone. It competed on experience, brand, and distribution channel. It turned a commodity molecule into a lifestyle brand. The generic is the ingredient; the brand is the product. That distinction is where the real value creation happens.
The biggest mistake I see is founders who target patent expiry without a differentiation thesis. If your plan is "make the same thing cheaper," you're entering a race you will lose to manufacturers in Hyderabad and Shenzhen who have lower cost structures than you ever will. The framework works best when patent expiry is your entry ticket — not your entire strategy. Use the expiry to get legal access to the technology, then build something the incumbent never would have built: a new form factor, a new distribution model, a new brand, a new customer segment.
Section 9
Opportunity Checklist
Score each item as yes (1 point) or no (0 points) to evaluate whether a specific patent expiry opportunity is worth pursuing.
Patent Expiry Opportunity Scorecard
The patent-protected product generates $500M+ in annual revenue, confirming substantial proven demand.
The core patent expires within 3–7 years, giving sufficient preparation time without excessive uncertainty.
No impenetrable patent thicket exists — secondary patents on formulations, delivery, or manufacturing processes are limited or challengeable.
Fewer than 5 competitors have filed regulatory applications (ANDAs, biosimilar applications) for this product.
A clear regulatory pathway exists in your target jurisdiction with a realistic approval timeline under 3 years.
You have access to manufacturing capacity that meets regulatory standards (cGMP, ISO, or equivalent).
You can articulate a differentiation thesis beyond price — better formulation, superior branding, new distribution channel, or underserved customer segment.
Section 10
Top Resources
01BookChristensen applies disruption theory specifically to healthcare, with extensive analysis of how generic drugs and biosimilars disrupt branded pharmaceutical business models. The chapters on value-chain evolution in pharma are directly applicable to anyone building a patent expiry strategy. Essential for understanding why incumbents consistently fail to defend against generic entry despite having every resource advantage.
02BookPorter's framework for analyzing industry structure is indispensable for evaluating patent expiry opportunities. The five forces analysis tells you whether a specific post-patent market will sustain margins or collapse to commodity pricing. The sections on barriers to entry and supplier power are particularly relevant for assessing manufacturing and regulatory moats in generic markets.
03BookThe foundational text on why incumbents struggle to respond to lower-cost entrants — which is precisely what patent expiry enables. Christensen's explanation of why rational managers at branded pharmaceutical companies consistently cede market share to generics (because the margins look unattractive relative to their existing business) is the theoretical backbone of this entire framework.
04BookSlywotzky's concept of value migration — how economic value flows from outdated business designs to new ones — maps perfectly onto patent expiry dynamics. When a patent lapses, value migrates from the incumbent's pricing power to the entrant's cost structure and distribution innovation. The framework for identifying where value is flowing next is directly applicable to building a patent expiry pipeline.
05Academic paperPorter's updated treatment of his five forces framework, with particular relevance to understanding how patent expiry reshapes industry structure. When a patent expires, the "threat of new entrants" force shifts dramatically — this essay gives you the analytical tools to predict whether that shift will create opportunity or merely redistribute thin margins among many competitors.
One more thing worth noting: this framework is expanding beyond pharma. As patents expire on key technologies in batteries, semiconductors, gene editing, and advanced materials, the same playbook applies. The founders who are building patent expiry pipelines outside of pharmaceuticals right now are playing a game with far less competition and potentially larger outcomes.
